Incretin bosed therapies for type 2 diabetes mellitus

Sujoy Ghosh*, Andrew Collier, Tarik Elhadd, Iqbal Malik

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

The incretin effect denominates the phenomenon that oral glucose elicits a higher insulin response than intravenous glucose. Glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide are the principal hormones responsible for incretin effect. In patients with type 2 diabetes the incretin effect of these hormones is Impaired. Therapeutic approaches for enhancing the incretin action include degradation resistant GLP-1 receptor agonists (incretin mimetics) and inhibitors of dipeptidyl peptidase-IV (DLP-IV) activity (incretin enhancers-gliptins). These groups of medications have similar efficacy with regards to glycaemic improvement (reduction of HbA1c between 0.5 to 1.1%) and have side-effects like nausea. The incretin mimetics are injectable agents and are more likely to reduce weight or be weight neutral when compared to the oral gliptins. Long-term studies are essential to determine the real potential and role of these newer agents in the management of type 2 diabetes.
Original languageEnglish
Pages (from-to)373-383+388
JournalJournal of the Indian Medical Association
Volume106
Issue number6
Publication statusPublished - Jun 2008
Externally publishedYes

Keywords

  • Dipeptidyl peptidase-IV (DPP-IV) inhibitors
  • Glucagon like peptide-1 (GLP-1)
  • Incretin
  • Type 2 diabetes

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Incretin bosed therapies for type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this